This retrospective multicenter study reviews the role of acute percutaneous transluminal coronary angioplasty in the treatment of cardiogenic shock complicating acute myocardial infarction to determine whether early reperfusion affects in-hospital and longterm survival. From 1982 to 1985, 69 patients were treated with emergency angioplasty to attempt reperfusion of the infarctrelated artery. Balloon angioplasty was unsuccessful in 20 patients (group 1) and successful in 49 patients (group 2).
This retrospective multicenter study reviews the role of acute percutaneous transluminal coronary angioplasty in the treatment of cardiogenic shock complicating acute myocardial infarction to determine whether early reperfusion affects in-hospital and longterm survival. From 1982 to 1985, 69 patients were treated with emergency angioplasty to attempt reperfusion of the infarctrelated artery. Balloon angioplasty was unsuccessful in 20 patients (group 1) and successful in 49 patients (group 2).
Initial clinical and angiographic findings in the groups with unsuccessful and successful angioplasty were similar with respect to age (60.5 ± 2.3 versus 57 ± 1.8 years), infarct location (65% versus 65% anterior) and gender (65% versus 67% male). Hemodynamic variables in the two groups, including systolic blood pressure (68 ± 4.3 versus 73 ± 1.6 mm Hg), left ventricular end-diastolic pressure (24.4 ± 2.4 versus 27 ± 1.0 mm Hg) and initial ejection fraction (28.5 ± 4% versus 32 ± 2%), were also similar. Twenty-nine patients received thrombolytic therapy with Cardiogenic shock develops in 5% to 10% of patients hospitalized with acute myocardial infarction (1, 2) . Despite dramatic improvements in acute coronary care, the 90% mortality rate associated with cardiogenic shock remains essentially unchanged (3, 4) . Pathologic studies (5.6) demonstrate extensive myocardial necrosis associated with thrombotic occlusion of coronary arteries. Decreased myocardial perfusion results in progressive myocardial necrosis which perpetuates the vicious cycle of the shock state (7.8) . De-Wood et al. (9) demonstrated that rapid surgical revascularization of the infarct-related artery resulted in a dramatic survival benefit in selected patients. Data from thrombolytic trials with respect to outcome in cardiogenic shock are limited. Percutaneous transluminal coronary angioplasty is an effective method of establishing coronary artery patency and can be more rapidly applied than can surgical revascularization. A few series have reported (10) (11) (12) (13) preliminary data on a survival advantage in patients with cardiogenic streptokinase; the overall rate of reperfusion was 34%. Group 1 patients had a short-term survival rate of 20%, compared with 69% in group 2 patients (p < 0.0005).
Thirty-eight patients survived the hospital period and were followed up for 24 to 54 months (mean 32.5 ± 2.4). Five patients (all in group 2) died during follow-up. The long-term incidence rate of congestive heart failure was 19%, arrhythmia 21 %, need for repeat angioplasty 17 % and coronary artery bypass grafting 26%. Twenty-four month survival was significantly better in group 2 patients (54%) versus group 1 patients (11 %, p = 0.003).
It is concluded that emergency coronary angioplasty improves initial and long-term survival in cardiogenic shock complicating myocardial infarction with survival contingent on establishing reperfusion. Patients who survive cardiogenic shock return to normal activity with a low incidence of recurrent cardiac complications.
(J Am Coll CardioI1991; 17:599-603) shock complicating acute myocardial infarction who undergo successful angioplasty of the infarct-related artery. We (12) previously reviewed the results of angioplasty in 24 patients and demonstrated a survival advantage in those with successful reperfusion of the infarct-related artery. We have now expanded our study to determine which factors predict successful angioplasty. This study reviews our multicenter experience with angioplasty therapy in patients with cardiogenic shock complicating acute myocardial infarction. The objectives of this study were I) to determine whether emergency angioplasty in the setting of acute myocardial infarction complicated by cardiogenic shock improves initial and long-term survival; 2) to delineate those factors that favorably or adversely affect survival; and 3) to determine the incidence of recurrent cardiac events and overall functional status in these patients after hospital discharge.
Methods
Study patients. Medical centers that published preliminary data in 1985 reviewing experience with cardiogenic shock complicating acute myocardial infarction were contacted in November 1986. Participating institutions included the University of Michigan Medical Center, Ann Arbor, Michigan; Mercy Medical Center, Des Moines. Iowa; Good Samaritan Hospital, Phoenix, Arizona; and Klinikum der Johannes Gutenberg-Universitat, MaiOl, Federal Republic of Germany. Data were collected on experience with coronary angioplasty therapy of cardiogenic shock from January 1982 to July 1985.
Myocardial infarction was defined as 1) chest pain consistent with myocardial ischemia; 2) ST segment elevation of at least 1 mm in electrocardiographic (ECG) limb leads or at least 2 mm in precordial leads; and 3) serum creatine kinase (CK) MB isoenzyme elevation.
Cardiogenic shock was defined as 1) a systolic blood pressure <80 mm Hg without inotropic or intraaortic balloon pump support; 2) a systolic blood pressure <90 mm Hg with inotropic or intraaortic balloon pump support; 3) evidence of adequate volume expansion demonstrated by a pulmonary capillary wedge pressure> 12 mm Hg or a left ventricular end-diastolic pressure> 18 mm Hg.
The final study group comprised 69 patients. All patients underwent emergency coronary angioplasty. Twenty patients (group 1) had unsuccessful reperfusion with balloon angioplasty; 49 patients (group 2) had successful reperfusion of the infarct-related artery. Patients were treated with sympathomimetic, vasodilator, cardiac glycoside and antiarrhythmic drugs and intraaortic balloon counterpulsation at the discretion of the staff cardiologist.
Coronary angioplasty. Angioplasty was performed with standard angioplasty guiding catheters and steerable balloon systems. After initial coronary angiograms were obtained, attempts were made to pass the balloon catheter system across the culprit lesion. When successful, the balloon catheter was serially inflated until the angioplasty result was deemed adequate by an interventional cardiologist. Successful angioplasty was defined as a reduction in luminal narrowing by >20% to a residual narrowing of <50% of the coronary luminal diameter. Angioplasty of only the infarctrelated artery was attempted in each patient. The decision to perform coronary angioplasty was made by the interventional cardiologist based on the anatomic characteristics of the coronary arteriogram.
Clinical follow-up. All surviving patients were followed up clinically after hospital discharge for a mean of 32.5 ± 2.4 months (range 24 to 54). A study physician or nurse contacted all patients by telephone; if the patient could not be contacted directly, his or her personal physician was interviewed or the medical chart was reviewed.
Statistical analysis. All numerical results are expressed as mean values ± SEM. Tests for differences between the means were performed with two-tailed student t tests for analytical data. Discrete variables were analyzed with the chi-square test or Fisher exact test where appropriate. A p value < 0.05 was considered statistically significant. Cumulative survival was calculated by the life-table method. Differences between survival curves were analyzed by the log-rank method. 
Results
Clinical data (Tables 1 and 2 ). There were no differences between patients in group 1 (unsuccessful angioplasty) and group 2 (successful angioplasty) with respect to age, gender or history of previous myocardial infarction (Table 1) . Median symptom duration (the onset of chest pain to attempted reperfusion) was similar in group 1 and group 2 (4 versus 5 h); 70% of group 2 patients had successful reperfusion within 12 h. Both groups had a high incidence of anterior myocardial infarction and an equal frequency of inferior infarction. Isolated lateral or posterior myocardial infarction occurred rarely. Peak serum CK MB isoenzyme activity was similar in both groups. Group 2 patients demonstrated a trend toward earlier peak CK MB activity (13 ± 7.4 versus 15 ± 10 h; p = NS). Intraaortic balloon counterpulsation was used with equal frequency in both groups.
Hemodynamic variables ( Table 2 ) obtained during cardiogenic shock were similar in the two groups. No statistically significant difference was found with respect to systolic blood pressure, left ventricular end-diastolic pressure, car- diac index or initial ejection fraction determined at acute angiography. Adjunctive thrombolytic therapy. Twenty-nine patients (8 in group 1 versus 21 in group 2, p = NS) received thrombolytic therapy with streptokinase at the time of angioplasty. Four patients received 1.5 million U of intravenous streptokinase (3 patients in group 1. 1 patient in group 2): the remaining 25 patients received intracoronary streptokinase (30,000 to 250,000 U). The overall reperfusion rate with thrombolytic therapy was 34%. Survival ( Fig. 1 and 2 ). In-hospital (7 day) survival was significantly better in group 2 patients than in group 1 patients (69% versus 20%, p < 0.0005) ( Fig. 1) . A long-term survival advantage persisted in group 2 patients. Patients were followed up clinically for a mean of 32.5 ± 2.4 months. At the time of follow-up 55% of group 2 patients were alive compared with 20% of group 1 patients (p < 0.002) (Fig. 2) .
The rate of survival to 24 months was 54% for group 2 patients versus 11% for group 1 patients (p = 0.003). Mean time to follow-up 32.5 months (range 24 to 54). NYHA = New York Heart Association: PTCA = percutaneous transluminal coronary angioplasty. ful angioplasty (group 2) and improved survival had a strong trend toward a higher incidence of single vessel coronary disease. Group 1 patients had an 80% incidence rate of multivessel disease compared with a rate of only 53% in group 2 patients (p = 0.07), Clinical follow-up (Table 3 ). Patients surviving cardiogenic shock had a low incidence of congestive heart failure (19%) requiring medical treatment and the majority of patients (94%) had New York Heart Association functional class I or II symptoms. Serious arrhythmias requiring treatment occurred in 21 % of patients. During the clinical follow-up period. 48% of patients underwent repeat catheterization with 17% requiring repeat angioplasty; 26% of patients were referred for coronary artery bypass grafting. A full active life-style was reported by 77% of patients; 17% reported moderate limitation of activity, whereas 6% were severely limited by cardiac symptoms.
Univariate analysis demonstrated that patients with success-

Discussion
Role of coronary angioplasty therapy in the management of cardiogenic shock. This question was evaluated in four centers experienced in interventional therapy of acute myocardial infarction. Because of the grave prognosis associated with cardiogenic shock complicating acute myocardial infarction we did not believe that true informed consent for a randomized controlled trial was possible. In lieu of a controlled trial we developed carefully defined rigorous hemodynamic and myocardial infarction inclusion criteria for the registry and followed up patients longitudinally over time to determine both the short-term and long-term results of aggressive management of this patient group. Because this study is not a controlled trial, a certain unrecognized selection bias may have been introduced. Only those patients surviving to undergo cardiac catheterization with suitable coronary anatomy could undergo angioplasty. We (10) have previously reported a mortality rate >80% for patients treated with conventional medical therapy during this same period. Therefore. in this specific patient group our current study suggests that angioplasty in the setting of acute myocardial infarction complicated by cardiogenic shock yields a high rate of coronary artery recanalization and imparts a survival advantage in those patients with successful reperfusion of the infarct-related artery. The mortality rate in patients with unsuccessful angioplasty was 80%. a rate essentially identical to that in conventionally treated historical control patients. The mortality rate in those patients with successful reperfusion of the infarct-related artery was reduced to 31% (p = 0.0005). Further, a long-term survival benefit persisted in patients treated with a successful reperfusion strategy.
Previous studies. The role of percutaneous trans luminal angioplasty in the treatment of cardiogenic shock complicating acute myocardial infarction has been reviewed by relatively few investigators. O'Neill et al. (11), in a cohort of 27 patients with cardiogenic shock complicating acute myocardial infarction, reported an in-hospital mortality rate of 67%; this rate was dramatically reduced to 25% in patients treated with successful emergency angioplasty of the infarct-related artery. Brown et al. (12) in a preliminary report described similar results in a series of 28 patients; the mortality rate in their study was 82% on those without reperfusion of the infarct-related artery but only 42% in those with reperfusion. Other preliminary reports (13, 14) described lowered mortality in patients with cardiogenic shock and acute myocardial infarction after successful reperfusion of the infarct artery. We (10) previously reported our 10 year experience of angioplasty therapy for cardiogenic shock and acute myocardial infarction. The mortality rate in patients treated without reperfusion of the infarct artery was 80% as compared with 23% in patients with successful reperfusion of the infarct -related artery. Recanalization of the infarct -related artery with angioplasty in patients with cardiogenic shock and acute myocardial infarction was achieved in 71 % of the patients in the present study. Other angioplasty series (lO-IS) have reported similar reperfusion rates of 54% to 88% for patients with cardiogenic shock.
Disappointing results with respect to survival in patients with multivessel disease have been previously reported (10) . In our study, patients with multivessel disease had an overall mortality rate of 62%. Despite successful angioplasty 31 % of patients died; 66% of these patients who died had multivessel coronary artery disease and only 33% had single vessel disease. The majority of our patients underwent angioplasty within 4 h of symptom onset; improved survival was documented in patients undergoing angioplasty many hours after this critical period. Animal studies (16) have demonstrated a beneficial effect of late reperfusion on limitation of infarct expansion and aneurysm formation independent of myocardial salvage. Force et al. (17) demonstrated that with late coronary reperfusion an acute reduction in diastolic and systolic infarct expansion occurs in the dog. Furthermore, JACC Vol. 17, No.3 March I. 1991:599-603 delayed reperfusion may improve the rate and extent of infarct healing.
Role of thrombolytic therapy. The efficacy of thrombolytic therapy in the setting of cardiogenic shock complicating acute myocardial infarction was disappointing in our study. Although thrombolytic therapy offers a rapid method of achieving reperfusion, the frequency of successful recanalization by this method remains low. Mathey et al. (18) and Rentrop et al. (19) reported low rates of thrombolysis in shock patients treated with intracoronary streptokinase. Neither study demonstrated any survival benefit in patients treated with thrombolytic therapy alone. Further, the Gruppo Italiano per 10 Studio della Streptochinasi nell'Infarto Miocardico (GISSl) study (20) reported a high mortality rate in patients with cardiogenic shock treated with intravenous streptokinase.
Clinical implications. The role of thrombolytic therapy and the need for further angioplasty in the setting of acute myocardial infarction remains a highly controversial topic. Recent results from GISSI-II (unpublished observations), the European Cooperative trial (21) , the Should We Intervene Following Thrombolysis (SWIFT) trial (22) and the Thrombolysis in Myocardial Infarction (TIMI) II-A trial (23) have all strongly suggested that watchful waiting is the correct approach for the majority of patients suffering from a relatively uncomplicated acute myocardial infarction. The role of early intervention after thrombolysis in higher risk patients (patients> 75 years old, or patients with extensive myocardium at risk) is unknown. Further, the use of early aggressive coronary angioplasty without thrombolysis in uncomplicated myocardial infarction is currently being evaluated. It appears, however, that in the setting of acute myocardial infarction complicated by cardiogenic shock a survival advantage is conferred by direct angioplasty of the infarct-related artery and that watchful waiting after thrombolysis is not a viable option in this high risk setting.
This clinical registry suggests that successful angioplasty may significantly improve the dismal initial and long-term survival of patients with acute myocardial infarction complicated by cardiogenic shock. Long-term clinical follow-up demonstrates that survivors return to normal activity with a relatively low incidence of recurrent cardiac complications.
